Member Info for WedME

Part 4.

In conclusion this information means SNG001 can be used over short and long periods of time without the adverse effects seen with the IV and S.C. versions, and unlike the other two can be used both safely and effectively with corticosteroids, which is crucial in interferon beta 1-a’s use as a therapeutic during this pandemic - where steroid use is seen as an essential part of treatment - and in treatment of respiratory, autoimmune, cancer and other diseases. 

Because of the widespread of this pandemic; the need for many treatment forms is needed due to that fact that one is simply not able to treat everyone. Thus the two other forms of interferon beta-1a will have a place in treatment of COVID-19. This post is to differentiate between the three main forms of interferon beta-1a’s modes of delivery and their resulting effect; not to adversely speak against the use of IV and S.C. versions which will no doubt also be of use to many people during this pandemic and beyond.

Wed

Long term use of interferon beta-1a treatment: https://pubmed.ncbi.nlm.nih.gov/27237769/

Systemic activation seen with COVID-19 patients: https://www.pnas.org/content/117/40/25018#:~:text=with%20viral%20load.-,Systemic%20complement%20activation%20is%20associated%20with%20respiratory%20failure%20in%20COVID,inhibitors%20in%20future%20clinical%20trials.

Lung comparison of COVID-19 and ARDS patients: https://www.nejm.org/doi/full/10.1056/NEJMoa2015432

Steroids limits interferon beta-1a signalling: 

https://mcb.asm.org/content/30/19/4564

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235433/

Failure in use of intravenous interferon beta-1a in ARDS patients: https://pubmed.ncbi.nlm.nih.gov/32065831/

Synairgen current trial data: http://www.isrctn.com/ISRCTN14241621

Part 3.

The thing that truly sets SNG001 apart from the others, in efficiency and side effects, is it’s patented mode of delivery. The use of interferon beta-1a as treatment in COVID-19 and other respiratory diseases lie in the ability to get interferon beta-1a to the lungs in the most efficient way to stop the inflammatory process caused by the autoimmune response and resulting tissue damage. Many of the adverse side effects seen with the IV and S.C. versions of interferon beta-1a arise from their mode of delivery to the lungs. They must travel through the blood stream to reach the lungs and this is where the most adverse side effects arise and result in a lower bioavailability of the drug. The higher the blood levels of exogenous interferon beta-1a the more severe the side effects are seen. The S.C. version has been seen to actually increase the severity of autoimmune illness due to it’s delivery form and further sets it apart from SNG001. This is why SNG001 is so unique. It is able to mimic the SARS-COV-2 virus itself and directly deliver interferon beta-1a to the lungs which immediately begins to stop the replication of the virus and thus aids in the healing. This is why SNG001 had such remarkable results from the hospital trials with a 79% reduction in development of severe disease and over twice as quick recovery time without severe side effects. 

The reason for the lack of adverse side effects with SNG001 lies in the fact that by nebulising interferon beta-1a; it is able to be delivered at a lower dose directly to the lungs to be instantly taken up by the cells and thus bypassing the need to use the blood stream as a carrier. The result is that interferon beta-1a blood levels seen with SNG001 are only one-tenth of those seen with IV and S.C. versions. Hence drastically diminishing any side effects and maximising SNG001’s bioavailability. The effective low dose delivered directly to the target area is also why SNG001 can be used over the whole course of disease treatment, with other drugs, rather than just as a preventative or early treatment.

Part 2.

Before the nebulised version of interferon beta-1a - SNG001 - the two main versions of interferon beta-1a treatment have been subcutaneous and intravenous. While these have shown efficiency in treatment of various diseases, their achilles heel, so to say, has been their history of adverse side effects which include flu-like symptoms, headache, joint pain, sores, liver damage, depression, ubiquitary arthralgia, and, rather ironic in this setting, shortness of breath. 

The lung damage seen in COVID-19 patients share many similarities to the lung damage seen in ARDS patients and has been documented in comparative autopsies of COVID-19 and ARDS patients. This is of particular interest as one of the main versions of IV interferon beta-1a currently in phase testing, and WHO trials, failed to show any significant effect towards the treatment of ARDS vs placebo in a randomised clinical trial published in a peer reviewed paper and results did not support the use of intravenous interferon beta-1a as treatment and management of ARDS. Adverse effects seen in this trial included fever, rigors, and tachycardia. 

One of the biggest points against IV and S.C. interferon beta-1a versions as treatment in a hospital setting, however, is seen with their inability to be efficiently used with corticosteroids such as dexamethasone, a primary treatment for COVID-19 patients, due to their dampening of anti-viral responses and inhibitory effect on interferon beta-1a signalling. 

They cannot, in other words, be used with dexamethasone which greatly diminishes their use as treatment in a COVID-19 and respiratory illness setting. This has enormous implications as SNG001 has been proven to work extremely well with corticosteroids such as dexamethasone, and with it’s patented use with steroids makes it a game changing drug in the treatment of COVID-19 and ARDS patients, to name but a few. 

Part 1.

I’d like to begin with saying I believe that there is a need for several different treatments for not only this pandemic but also other illness’ so I hope there will be many more developed. I know there are board members here who are invested in other versions of Interferon Beta-1a so believe me when I say I am not trying to deramp any other investment. I am simply trying to inform what differentiates this version of interferon beta 1a from others as this is a board for Synairgen and SNG001. I’m sure any members have done their research and will remain happy with their other investments regardless of information in this post.

All links to evidence are at the end of this series of posts.

In the treatment of COVID-19 patients - the use of interferon beta-1a has received a growing recognition as a primary source of treatment in both prophyatic treatment and during the course of the disease. There are several versions of interferon beta-1a currently undergoing trials. In this post I will differentiate between the main three versions under investigation as use for treatment of both COVID-19 patients and other diseases. I will submit evidence toward why I believe SNG001 would be considered the most efficient therapeutic with fewest side effects of the three in relation to treatment.

We know now from various peer reviewed studies that COVID-19 causes an over-reaction of the immune system through the up-regulation of anaphylatoxins C5a and C3a and their resulting down-regulation of the body’s natural antiviral interferon beta-1a production - the body’s strongest viral defence. Without the anti-viral effect of interferon beta-1a, and it’s ability to efficiently stop the virus from replicating, the immune system is kicked into overdrive in an attempt to defend itself from harm. This effect unfortunately mimics an autoimmune disease and causes the body to falsely target healthy tissue for destruction resulting in ‘Long Covid’ - a similar effect seen with Lupus and MS - two autoimmune diseases. This damaging effect is particularly seen in the lungs as they are the entry point of the SARS-COV-2 virus and thus the first affected by the tissue damage caused by the autoimmune response. 

To combat this autoimmune effect; the need for exogenous interferon beta-1a is seen as crucial in both prophyatic treatment and during the course of the disease in order to counter the viral threat and restore balance to the immune system.

However, not all interferon beta-1a treatment versions are equal in their efficiency, bioavailability, and resulting side effects. 

The IV version of Interferon beta-1a's serious adverse side effects are well known. SNG001 is completely different and can't be compared. Not to mention it has been used on COVID-19 patients already with some rather stunning results. Take some time to look at the research that this board has produced to get an understanding of the major differences. The difference between the different versions is the subject of my next write up which I'll hopefully have done by tomorrow.

@gkb47 ha yeah, thankfully the UK quickly switched from that approach. It only took everything getting out of hand first..

I have family in Sweden. They are fully experiencing a second wave and now have more cases per 100k than the UK (Sweden 953.37 vs UK 842.97) Stockholm is experiencing the largest spike which rules out the 'herd immunity' approach since they were hit hardest during the first wave. Sweden also have more deaths than all the surrounding countries put together and then some. Their economy has also been hit harder than any Scandinavian country. In other words their approach has not worked and would have been an even larger disaster here in the UK had they adopted the same approach. Sweden now have much stricter guidelines in place to deal with the steep surge they are experiencing and people in high risk groups are not allowed to work.

A positive end to the week and certainly a somewhat interesting glimpse into Woodstock's life - what a way to start the weekend.

Great research and posts across the board this week.

Thank you all for your input.

Pmjh, you've outdone yourself yet again. I'm fully beginning to picture you in my head as Magnum P.I.

The coming week is looking very exciting with many events occurring that pmjh has outlined.

SNG001's preventative abilities with anything from Covid-19 to the flu, and any future viruses, is enough on it's own to push the company value beyond previous highs. A universal viral 'vaccine' without serious adverse side effects.

Then adding COPD, ARDS, MS, cancer, and autoimmune treatment, to name but a few, to the count and you have a product that will prevail, with many uses, both during and long beyond this pandemic - a pandemic which continues to worsen and, sadly, won't be going anywhere soon with the world hitting a new global daily high yesterday of over 350000 new infections, the following hospitalizations and, worst of all, deaths; further highlighting the need for SNG001 among other treatments.

'Long covid' and prophylactic treatment are only the latest of many legs SNG001 to stand on. With approval it will hit the ground running and commercialisation will swiftly follow.

Anyone trying to tell you that SNG001 only has one play or unable to see the prolonged commercial value from it's many uses has either not done enough research on nebulised interferon beta-1a or is wilfully trying to confuse you for their own gain. The facts of it's many treatment abilities are not even up for debate.

Use the research here along with your own to make your mind up on this and take control from both the ramping and deramping crowds. I've learnt by now that anyone bragging about large specific sums they have made either buying or selling a stock are usually, in a medical opinion, talking out of a different hole than the one located on their face.

I'll personally place more faith in product developed by a professor who is one of the world's foremost experts on respiratory and immune disease with more than 30 years of experience, and who was recently knighted for his achievements, than an anonymous person on a chat board.

I've upped of the value of this company, in my own personal opinion, which I will keep to myself, after further research this week.

I want to see much less suffering and more of my own home this winter. To me SNG001, after researching, is a key element in doing just that, and the reopening of our society.

Have a great weekend everyone!

Blue days ahead

Let's focus on the great product that SNG001 is and all 'patience' will be rewarded. So many positive things coming shortly. I'm definitely focusing on that. This drug works and will take off regardless who uses it first.

Now there is a market!

@Topupme. Synairgen have all the patents in place and this will be a big money maker drug solely on it's multi use beyond Covid-19. I think we are agree the government could have managed the whole Covid-19 pandemic better but I think there is more going on than we know. We'll see shortly as there are plenty of updates next week.

@Tonlin. I don't trust big pharma as far as I an throw them but I do trust their love of money and something as valuable as this with it's many uses. And the fact it can be used time and time again with the same patients leads me to think they will be targeting it.

@pmjh I agree, my sister is a professional opera singer who tours the world and would definitely need this.

@JSP123. Just trying to do my small part to spread info that will stop this pandemic. Glad to help!

Tonlin, I think the product is good and valuable enough to hold up against any resistance. And it will surely be on the radar of big Pharma looking to licence it or outright buy it. It's a money maker and that always wins in the end whether it stays with Synairgen or gets bought out.

The IV version interferon beta-1a has adverse effects if taken over a long period of time ie with cancer treatment, however, what makes SNG001 so exciting is that it does not have the same side effects due to it's delivery form. It's a safer and better version of Interferon beta-1a that people have basically been waiting 40 years for. And that's what makes it so unique. Plus you wouldn't need to continuously take it but even if you did it seems very safe. It is a natural part of your immune system so it wouldn't damage or disrupt it.

I think the use in other countries will propel SNG001'S use in the UK. Plus we don't know what is happening behind the scenes in the UK. Could very well have a big UK announcement following an emergency approval.

Yes that is what I meant, Dumpunter. I haven't slept yet after my shift. The dosage needed is very small in comparison to other treatments that the production cost is considerably lower. And there are large supplies already available.

Exactly, Welshfalcon. This is something that can be used to prevent ANY virus including those on the way, and the flu which many older and high risk people are unable to get a vaccine towards because of medical conditions. Just imagine when the next virus comes along and a preventative drug is needed before a vaccine is produced. SNG001 will be ready and highly effective without the serious adverse effects. And then there are all the other uses such as COPD, ARDS, MS, Autoimmune disease etc. A wonder drug with a very, very big market value.

@CityTTrader. This is a game changer drug, indeed.

@maximillion69. Just doing my job. I think the need for this drug, especially in France, will see plenty of doctors taking the MAP route. What is a bit of paperwork to save a lot of lives and heal the sick. Besides hospitals can order large amounts of it.

Now that is surely an interesting idea, TT. I think that next weeks media exposure from the various events involving Synairgen could very well aid in that.

@maximillion69. I know of several people in the health sector who are heavily invested in this. Even before my input. It's very easy to see the upside to this. I've spent more time in ICU wards than at home this year. I'm not looking forward to this winter which is why I'm excited about the recent developments with the production of this drug.

@Oxford12. That certainly seems interesting. I'm sure they have the use of SNG001 as a preventative measure strongly in mind.

@sparkyboy1. I think we'll see more than £1 added shortly due to the drug itself.

@Bluemoon73. There are surely many things going on behind the scenes. But as I mentioned earlier, the global need for therapeutics and especially preventative ones is in high demand that will only increase. The UK government will eventually have to get on board if they haven't already behind the scenes.

Thank you, VP007. I think there has been a major shift towards therapeutics over vaccines, in the last months especially. It doesn't matter what the UK government decide to do or not. The GLOBAL need for therapeutics, and especially preventative ones, are high in demand and that demand is only getting greater. SNG001 will prevail regardless.

Part 2

There is also no shortage of interferon beta-1a, unlike remdesvir, dexamethasone, and monoclonal antibodies, as there already exists large supplies of the drug, due to it being around for years, and production is quick and cheap. This means that Synairgen's costs will remain minimal and profits maximal.

Monoclonal antibody treatments approved over the last 20 years cost an average of $96,731. And Trump's unapproved REGEN COV2 treatment course cost taxpayers $386,924. Then comes the mounting evidence against the use of antibodies as a treatment towards this virus as they give the same over-activation response of the immune system.

With the world seeing an explosion in infections, hospitalizations, and deaths - the need for multiple treatments is crucial.

SNG001 is now heads above any other treatment, with low production costs and large supplies of interferon beta-1a available, it will be ready to save many lives, heal the sick, and maximise company profits. There seems to be no end to the positives with this and we will see the fruit of it in the next few days.

Bat model: https://www.ft.com/content/743ce7a0-60eb-482d-b1f4-d4de11182fa9

Monoclonal antibody cost: https://www.theguardian.com/us-news/2020/oct/08/trump-covid-treatment-health-insurance

Coronavirus world record infections: https://www.google.com/amp/s/mobile.reuters.com/article/amp/idUSKBN26T33H